Inhalation of Therapeutic Monoclonal Antibodies for Respiratory Diseases: Challenges and Opportunities
Heuze-Vourc'h N, Respaud R, Dalloneau E, Vecellio L.
RDD Europe 2017. Volume 1, 2017: 11-18.
Abstract:
Inhalation is a non-invasive delivery route and can be used to target drugs directly to the lungs, limiting the exposure of secondary organs. It is thus an attractive alternative to the intravenous, intramuscular, and subcutaneous routes for the delivery of therapeutic monoclonal antibodies (mAbs) for respiratory diseases, which display limited transfer from the blood into the lungs. Only a few comprehensive studies have investigated the inhalation of mAbs, but they have highlighted the relevance and feasibility of developing effective inhaled mAbs to treat respiratory diseases. Although challenges must still be overcome, the first antibody fragment (ALX-0171 nanobodyTM, Ablynx) delivered by inhalation has completed Phase 1 clinical trials, demonstrating that inhaled antibody-based treatments may not be far away.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
